Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
During 2016, Faber further strengthened its professional lineup in key disciplines...
Clinical Trial Agreements
Jill C. Alvarez has joined the New York office as senior counsel and will focus on the most complex, clinical-related contracting challenges. She most recently served as assistant general counsel for Vertex Pharmaceuticals.
“One issue faced by trial sponsors is how to assess the performance of contract research organizations (CROs) operating around the world on their behalf. I’ve done a lot of work developing accountability measures for master agreements. When you have objective metrics, hard data replaces finger pointing and vendors understand expectations.”
She also expects that her experience with expanded access programs will benefit clients. “This is a new area for many of them, and we can help them understand and weigh the business, safety and ethical issues.”
Jill E. Goodman has joined the firm’s Boston office as a contracts specialist. As a senior contracts specialist with Millenium Pharmaceuticals (now Takeda Oncology), she managed contracts throughout their lifecycle. “I’m used to managing high-volume, time-sensitive transactions without sacrificing quality,” she says.
“I’ve been impressed by Faber’s culture of mentoring and information sharing. Although each clinical trial client has a dedicated team of attorneys and contract specialists, there’s no silo mentality here, and our senior professionals have an open door policy. That means that clients actually have the entire firm’s resources at their disposal.”
M&A and Venture Financing
Timothy J. LaBua has joined Faber’s Boston office as senior counsel, concentrating on M&A, strategic partnerships and private financing. He was previously an attorney with Skadden, Arps, Slate, Meagher & Flom LLP, as well as the investment and operations counsel for a prominent hedge fund.
Tim will focus on emerging science-based opportunities, where his background in assessing value and structuring financial packages will be instrumental. “I’m experienced in analyzing the risk/reward of early-stage investments and in understanding the dynamics of competitive bidding situations,” he says. “I’ve represented both the buy and sell side of strategic transactions, so I recognize the pressure points for each. I balance a measure of realism with the desire to get the best result for my clients.”